These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7529489)

  • 1. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Nacey JN; Meffan PJ; Delahunt B
    Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Stoner E; Guess H
    Aust N Z J Surg; 1995 May; 65(5):360. PubMed ID: 7537957
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
    Stoner E
    Urology; 1994 Mar; 43(3):284-92; discussion 292-4. PubMed ID: 7510911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.
    Tewari A; Shinohara K; Narayan P
    Urology; 1995 Feb; 45(2):258-64; discussion 265. PubMed ID: 7531900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia.
    Vaughan D; Imperato-McGinley J; McConnell J; Matsumoto AM; Bracken B; Roy J; Sullivan M; Pappas F; Cook T; Daurio C; Meehan A; Stoner E; Waldstreicher J
    Urology; 2002 Dec; 60(6):1040-4. PubMed ID: 12475666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group.
    Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia.
    Sullivan MJ; Geller J
    BMC Urol; 2002; 2():2. PubMed ID: 11818031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group.
    Ekman P
    Eur Urol; 1998; 33(3):312-7. PubMed ID: 9555559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.
    Abrams P; Schäfer W; Tammela TL; Barrett DM; Hedlund H; Rollema HJ; Matos-Ferreira A; Nordling J; Bruskewitz R; Andersen JT; Hald T; Miller P; Kirby R; Mustonen S; Cannon A; Jacobsen CA; Gormley GJ; Malice MP; Bach MA
    J Urol; 1999 May; 161(5):1513-7. PubMed ID: 10210385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
    CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.